NOVOCURE LTD
NovoCure Limited (NVCR) develops and commercialises Tumour Treating Fields (TTFields), a non‑invasive therapy that uses alternating electric fields to disrupt cancer cell division. The company focuses on solid tumours, with approved indications and ongoing trials in brain, lung and other cancers. Revenue growth to date has been driven by increased adoption in the US and selected international markets, label expansions and expanding clinical evidence. Key considerations for investors include clinical trial outcomes, regulatory approvals, payer reimbursement and execution of commercial scale‑up. As a smaller-cap medical‑technology company (market cap about $1.58bn), NovoCure can be volatile: upside comes with execution and data risk, while setbacks in trials or reimbursement can affect the share price. This summary is educational and not personalised investment advice; potential investors should research further and consider risk tolerance and time horizon before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying NovoCure's stock with a target price of $24.79, indicating potential growth.
Financial Health
NovoCure is performing well with strong revenue and profit margins, indicating solid business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring NVCR
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Tumour Treating Fields
A differentiated technology targeting cell division that investors watch for clinical proof points, though trial outcomes can be binary and affect valuation.
Commercial Expansion
Revenue potential rests on wider adoption, geographic rollout and payer coverage; execution risk and reimbursement delays may temper near‑term growth.
Regulatory & Reimbursement
Approval decisions and payer policies shape market access; positive decisions can boost uptake, while unfavourable rulings can limit growth.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
